Morbidity after antiretroviral therapy initiation in HIV-1-infected children in West Africa: Temporal trends and relation to CD4 count

Pediatric Infectious Disease Journal

Volumn 32, Issue 4, 2013, Pages 354-360

  De Beaudrap, Pierre ^a   Boullé, Charlotte ^a   Lewden, Charlotte ^b   Gabillard, Delphine ^b   Nacro, Boubacar ^c   Diagbouga, Serge ^d   Fassinou, Patricia ^e   Hien, Hervé ^f   Laurent, Christian ^a   Msellati, Philippe ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b INSERM   (France)

^c Institut du Développement Rural   (Burkina Faso)

^d Centre National de la Recherche Scientifique et Technologique   (Burkina Faso)

^e ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

^f CENTRE MURAZ   (Burkina Faso)

Author keywords

AIDS defining infection; Children; Highly active antiretroviral therapy; HIV; Morbidity

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; MALARIA; MALE; MORBIDITY; MYCOSIS; OTITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; THRUSH; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV-1; HUMANS; INCIDENCE; INFANT; MALE; VIRAL LOAD;

EID: 84876297774     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318278b222     Document Type: Article

References (32)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010 UNAIDS. Available at: http://www.unaids.org/globalreport/Global-report.htm. Accessed July 28, 2011.
2. Stringer EM, Ekouevi DK, Coetzee D, et al.; PEARL Study Team. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA. 2010;304:293-302.
3. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 2006;296:292-300.
4. Sánchez JM, Ramos Amador JT, Fernández de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:863-867.
5. Nesheim SR, Kapogiannis BG, Soe MM, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics. 2007;120:100-109.
6. World Health Organization. Paediatric HIV and treatment of children living with HIV Available at: http://www.who.int/hiv/topics/paediatric/en/index. html. Accessed April 11,2012.
7. Dunn D; HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003;362:1605-1611.
8. Hainaut M, Ducarme M, Schandene L, et al. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 2003;22:62-69.
9. Soh CH, Oleske JM, Brady MT, et al.; Pediatric AIDS Clinical Trials Group. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
10. Ylitalo N, Brogly S, Hughes MD, et al.; Pediatric AIDS Clincial Trials Group Protocol 219C Team. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med. 2006;160:778-787.
11. Nacro B, Zoure E, Hien H, et al. Pharmacology and immuno-virologie efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. Bull World Health Organ. 2011;89:451-458.
12. Rouet F, Fassinou P, Inwoley A, et al.; ANRS 1244/1278 Programme Enfants Yopougon. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319.
13. Cook RJ, Erdman JN, Dickens BM. Respecting adolescents' confidentiality and reproductive and sexual choices. Int J Gynaecol Obstet. 2007;98: 182-187.
14. Tsiatis AA, DeGruttolaY Wulfsohn MS. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and CD4 counts in patients with AIDS. J Am Statist Assoc. 1995;90:27-37.
15. De Beaudrap P, Etard JF, Diouf A, et al.; ANRS 1215/90 Study Group. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal. Am J Trop Med Hyg. 2009;80:1047-1053.
16. De Beaudrap P, Rouet F, Fassinou P, et al. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2008;49:70-76.
17. Lewis J, Walker AS, Castro H, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: Effects on long-term T-cell reconstitution. J Infect Dis. 2012;205:548-556.
18. Oksendal BK. Stochastic Differential Equations: An Introduction With Applications. Berlin: Springer; 2003.
19. Spiegelhalter D, Thomas A, Best N, et al. Win BUGS User Manual. Cambridge, UK: Medical Research Council Biostatistics Unit; 2003.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2008.
21. Chiappini E, Galli L, Tovo PA, et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART AIDS. 2007;21:1607-1615.
22. Guillén S, García San Miguel L, Resino S, et al.; Madrid Group for Research on Pediatric HIV Infection. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006). HIV Med. 2010;11:245-252.
23. Alarcón JO, Freimanis-Hance L, Krauss M, et al.; NISDI Pediatric Study Group 2011. Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States. AIDS Res Hum Retroviruses. 2012;28:282-288.
24. Mulenga V, Ford D, Walker AS, et al.; CHAP Trial Team. Effect of cotri-moxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS. 2007;21:77-84.
25. Viani RM, Araneta MR, Deville JG, et al. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725-731.
26. Kourtis AP, Bansil P, Posner SF, et al. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics. 2007;120:e236-e243.
27. Gibb DM, Duong T, Tookey PA, et al.; National Study of HIV in Pregnancy and Childhood Collaborative HIV Paediatric Study. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
28. Violari A, Cotton MF, Gibb DM, et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
29. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115: e488-e494.
30. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. lancet. 2000;355:1331-1332.
31. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899.
32. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28:488-492.